Human Microbiome Market Size, Share | Report 2021, 2028

Human Microbiome Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs and Supplements), Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders, and Others) and Application (Therapeutics and Diagnostics) and Geography

  • Report Code : TIPBT00002233
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 188
Buy Now

The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021–2028.

The human microbiota consists of the trillions of symbiotic microbial cells harbored by each person mainly bacteria in the gut. The microbes, including bacteria, fungi, and viruses, are the disease-causing agent that accumulate over time, and the habitat in gut transforms their genetic activities and metabolic processes, resulting in an abnormal immune response against the substances and tissues that normally present in the human body. Several microbiome projects have been launched worldwide with the aim to understand the roles played by these symbionts and their impact on the health of human host. The growth of the human microbiome market is attributed to the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However strict government guidelines and lack of knowledge about detailed examination hinders the market growth.  

Market Insights

Increasing Incidence of Lifestyle Diseases

In the past few decades, researchers have come up with the clarity on the relation between human microbiome and lifestyle diseases such as cancer, diabetes, obesity, and depression. Changes in lifestyles and societal norms influence the microbiome at each stage of life. Altering the human microbiome can help eliminate such lifestyle diseases. As per World Health Organization, 13% of the world population (adults) was obese in 2016. According to the “The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation,” published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ whose composition and functionality contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), involving the transfer of feces from a healthy donor to the patient, is a potential treatment for obesity.

Diabetes is one of the global health emergencies of the 21st century. According to the International Diabetes Federation (IDF), the number of people suffering from diabetes in North America was ~46 million in 2017, which is expected to rise to 62 million by 2045, i.e., with the disease prevalence of ~35% during the forecast period. The reduced levels of Firmicutes Clostridia indicate the microbiome of patients with diabetes butyrate-producing bacteria and an increased ratio of Bacteroidetes: Firmicutes. Thus, diabetes can be prevented as well as treated by altering the microbiome by administration of prebiotics, probiotics, and fecal transplantation. Therefore, the increasing incidence of chronic lifestyle diseases is driving the human microbiome market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Human Microbiome Market: Strategic Insights

human-microbiome-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Product-Based Insights

Based on product, the human microbiome market is segmented into foods, medical foods, probiotics, prebiotics, drugs, diagnostic devices, and supplements. The probiotics segment is projected to hold the largest market share in 2021, and the prebiotics segment is anticipated to register the highest CAGR in the market during the forecast period.

Report Coverage

Disease-Based Insights

The human microbiome market, by disease, is segmented into diabetes, cancer, autoimmune disorders, obesity, mental disorders, and other diseases. The market for the human microbiome is emerging owing to rising incidences of lifestyle diseases such as cancer and diabetes. The obesity segment is expected to hold the largest share of the market in 2021, whereas the diabetes segment is estimated to register the highest CAGR during the forecast period.

Application-Based Insights

The human microbiome market, by application, is segmented into diagnostics and therapeutics. The therapeutics segment is projected to hold a larger market share in 2021, and it is further estimated to register a higher CAGR during the forecast period.

Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios. Companies in the human microbiome market focus on the collaboration strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world.

Human Microbiome Market Regional Insights

The regional trends and factors influencing the Human Microbiome Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Human Microbiome Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

human-microbiome-market-global-geography
  • Get the Regional Specific Data for Human Microbiome Market

Human Microbiome Market Market Report Scope

Report Attribute Details
Market size in 2021 US$ 718.95 Million
Market Size by 2028 US$ 2,921.68 Million
Global CAGR (2021 - 2028) 22.2%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product
  • Probiotics
  • Foods
  • Prebiotics
  • Medical Foods
  • Diagnostic Device
  • Drugs and Supplements
By Disease
  • Obesity
  • Diabetes
  • Autoimmune Disorders
  • Cancer
  • Mental Disorders
By Application
  • Therapeutics and Diagnostics
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Synthetic Biologics Inc.
  • DuPont
  • MaaT Pharma
  • Eligo Bioscience
  • Merck & Co. Inc
  • AOBiome LLC
  • Kaleido
  • Market Players Density: Understanding Its Impact on Business Dynamics

    The Human Microbiome Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

    Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

    Major Companies operating in the Human Microbiome Market are:

    1. Rebiotix Inc.
    2. Yakult Honsha Co., Ltd.
    3. Synthetic Biologics Inc.
    4. DuPont

    Disclaimer: The companies listed above are not ranked in any particular order.


    human-microbiome-market-speedometer

    • Get the Human Microbiome Market top key players overview

    Human Microbiome Market – by Product

    • Probiotics 
    • Foods
    • Prebiotics
    • Medical Foods
    • Diagnostic Devices
    • Drugs
    • Supplements

    Human Microbiome Market – by Disease  

    • Obesity
    • Diabetes
    • Autoimmune Disorders
    • Cancer
    • Mental Disorders
    • Others

     Human Microbiome Market – by Application   

    • Therapeutics
    • Diagnostics

    Human Microbiome Market – by Geography

    • North America

      • US
      • Canada
      • Mexico
    • Europe

      • France
      • Germany
      • Italy
      • UK
      • Spain
      • Rest of Europe
    • Asia Pacific (APAC)

      • China
      • India
      • South Korea
      • Japan
      • Australia
      • Rest of Asia Pacific
    • Middle East and Africa (MEA)

      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of Middle East and Africa
    • South and Central America (SCAM)

      • Brazil
      • Argentina
      • Rest of South and Central America

    Company Profiles

    • Rebiotix Inc.
    • Yakult Honsha Co., Ltd.
    • Synthetic Biologics Inc.
    • DuPont
    • MaaT Pharma
    • Eligo Bioscience
    • Merck & Co. Inc
    • AOBiome LLC
    • Kaleido
    • Seres Therapeutics
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    Product , Disease and Application and Geography

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

    Frequently Asked Questions


    What are the driving factors for the human microbiome market across the globe?

    The growth of the human microbiome market is attributed to the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However strict government guidelines and lack of knowledge about detailed examination hinders the market growth.

    What is human microbiome?

    The human microbiota consists of the trillions of symbiotic microbial cells harbored by each person, mainly bacteria in the gut. The microbes including bacteria, fungi and viruses are the disease-causing microbes that accumulate over time and changing their gene activity & metabolic processes and resulting in an abnormal immune response against the substances and tissues that normally present in the human body.

    What is the regional analysis in terms of human microbiome market?

    The Asia Pacific human microbiome market is analyzed based on the five major countries such as China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. The Asia Pacific region is expected to be the fastest-growing region among all other regions. The rise in the collaborations among the Asian countries and Western countries for the research activities and the extensive genomic research in China are to likely drive the human microbiome market in the forecast period. In May 2018, The Conference on Human Microbiome and Chronic Disease, hosted by the Institute of Microbiology, Chinese Academy of Sciences and Chinese Society of Biotechnology was held in China National Convention Center at Beijing. The aim was to promote research human microbiome and related technology. Thus, there is a huge potential for human microbiome market in the region during the forecast period owing to the above-mentioned factors.

    Trends and growth analysis reports related to Biotechnology : READ MORE..   


    The List of Companies - Human Microbiome Market

    1. Rebiotix Inc.
    2. Yakult Honsha Co., Ltd.
    3. Synthetic Biologics Inc.
    4. DuPont
    5. MaaT Pharma
    6. Eligo Bioscience
    7. Merck & Co. Inc
    8. AOBiome LLC
    9. Kaleido
    10. Seres Therapeutics